Pricing Log in Create free account

Biogen Inc. (BIIB) vs Nasus Pharma Ltd. (NSRX)

Biogen Inc. and Nasus Pharma Ltd. are both Drug Manufacturers General companies. Biogen Inc. is the larger, with a market value of $34.8B against $37.1M — 938.2× the size. Across the 9 metrics below, Biogen Inc. leads on 6 and Nasus Pharma Ltd. on 3.

Valuation

Metric BIIB NSRX Drug Manufacturers General median
P/E 40.96 — 24.54
P/S 3.43 — 3.39
P/B 1.82 n/m 5.00
Price to free cash flow 13.53 n/m 16.55
EV/EBITDA 15.66 n/m 13.82
EV/Sales 4.03 n/m 4.03
Earnings yield 2.44% — 2.98%
Free cash flow yield 7.39% 0.00% 4.46%

Profitability

Metric BIIB NSRX Drug Manufacturers General median
Gross margin 73.99% — 72.77%
Operating margin 12.35% — 18.77%
Net margin 8.32% — 8.27%
Free cash flow margin 25.33% 0.00% 17.18%
Return on equity 4.58% 0.00% 5.87%
Return on assets 2.76% 0.00% 2.57%
Return on invested capital 3.11% 0.00% 6.11%

Growth

Metric BIIB NSRX Drug Manufacturers General median
Revenue growth (TTM) 0.31% — 6.66%
EPS growth (last fiscal year) (21.38%) (231.82%) 21.81%
Revenue growth, 5-year CAGR (5.96%) — 4.75%
Net income growth, 5-year CAGR (20.22%) — 0.00%

Health

Metric BIIB NSRX Drug Manufacturers General median
Debt to equity 0.39 0.00 0.63
Current ratio 1.87 8.77 1.32
Net debt to EBITDA 0.84 0.26 1.15

Dividend

Metric BIIB NSRX Drug Manufacturers General median
Dividend yield — — 2.33%
Payout ratio — — 0.59

Size

Metric BIIB NSRX Drug Manufacturers General median
Market cap 34.77b 37.06m 123.73b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack